European Treaty Series - No. 135 Anti-Doping Convention Strasbourg, 16.XI.1989 Appendix – AMENDMENTS TO THE APPENDIX (approved by the Monitoring Group under Article 11.1.b of the Convention at its 47th meeting) (Strasbourg, 4 November 2017) THE 2018 PROHIBITED LIST - WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE : 1 JANUARY 2018 SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S.4.4, S.4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES Bolandiol (estr-4-ene-3β,17β-diol ); S0. NON-APPROVED SUBSTANCES Bolasterone; Calusterone; Any pharmacological substance which is not Clostebol; addressed by any of the subsequent sections of Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en- the List and with no current approval by any 20-yn-17α-ol); governmental regulatory health authority for Dehydrochlormethyltestosterone (4-chloro- human therapeutic use (e.g drugs under pre- 17β-hydroxy-17α-methylandrosta-1,4-dien-3- clinical or clinical development or discontinued, one); designer drugs, substances approved only for Desoxymethyltestosterone (17α-methyl-5α- veterinary use) is prohibited at all times. androst-2-en-17β-ol); Drostanolone; S1. ANABOLIC AGENTS Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Anabolic agents are prohibited. Formebolone; …………………………………………………… Furazabol (17α-methyl 1. ANABOLIC ANDROGENIC STEROIDS [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan- (AAS) 17β-ol); * Gestrinone; a. Exogenous AAS, including: Mestanolone; Mesterolone; 1-Androstenediol (5α-androst-1-ene-3β,17β- Metandienone (17β-hydroxy-17α- diol); methylandrosta-1,4-dien-3-one); 1-Androstenedione (5α-androst-1-ene-3,17- Metenolone; dione); Methandriol; 1-Androsterone (3α-hydroxy-5α-androst-1- Methasterone (17β-hydroxy-2α,17α-dimethyl- ene-17-one); 5α-androstan-3-one); 1-Testosterone (17β-hydroxy-5α-androst-1-en- Methyldienolone (17β-hydroxy-17α- 3-one); methylestra-4,9-dien-3-one); 4-Hydroxytestosterone (4,17β- Methyl-1-testosterone (17β-hydroxy-17α- dihydroxyandrost-4-en-3-one); methyl-5α-androst-1-en-3-one); ETS 135 – Anti-Doping Convention, 16.XI.1989 - The 2018 Prohibited List __________________________________________________________________________________ Methylnortestosterone (17β-hydroxy-17α- b. Endogenous** AAS when administered methylestr-4-en-3-one); exogenously: Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy- 19-Norandrostenediol (estr-4-ene-3,17-diol); 17α-methylestra-4,9,11-trien-3-one); 19-Norandrostenedione (estr-4-ene-3,17- Mibolerone; dione); Norboletone; Androstanolone (5α-dihydrotestosterone, Norclostebol; 17β-hydroxy-5α-androstan-3-one); Norethandrolone; Androstenediol (androst-5-ene-3β,17β-diol); Oxabolone; Androstenedione (androst-4-ene-3,17-dione); Oxandrolone; Boldenone; Boldione (androsta-1,4-diene- Oxymesterone; 3,17-dione); Oxymetholone; Nandrolone (19-nortestosterone); Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]- Prasterone (dehydroepiandrosterone, DHEA, 1'H-pyrazolo[3,4:2,3]-5α-androstane); 3β-hydroxyandrost-5-en-17-one); Quinbolone; Testosterone; Stanozolol; Stenbolone; and their metabolites and isomers, including Tetrahydrogestrinone (17-hydroxy-18a-homo- but not limited to: 19-nor-17α-pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3- 3β-Hydroxy-5α-androstan-17-one; one); 5α-Androst-2-ene-17-one; 5α-Androstane-3α,17α-diol; and other substances with a similar chemical 5α-Androstane-3α,17β-diol; structure or similar biological effect(s). 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β,17β-diol); 5-Androstenedione (androst-5-ene-3,17- dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone; Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone; Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. 2 ETS 135 – Anti-Doping Convention, 16.XI.1989 - The 2018 Prohibited List __________________________________________________________________________________ ……………………………………………………. 2. OTHER ANABOLIC AGENTS 2. Peptide hormones and Hormone Modulators, Including but not limited to: 2.1 Chorionic Gonadotrophin (CG) and Clenbuterol, selective androgen receptor Luteinizing Hormone (LH) and their modulators (SARMs, e.g. andarine, LGD-4033, releasing factors, e.g. Buserelin, ostarine and RAD140), tibolone, zeranol and deslorelin, gonadorelin, goserelin, zilpaterol. leuprorelin, nafarelin and triptorelin, in males; For purposes of this section: * “exogenous” refers to a substance which is not 2.2 Corticotrophins and their releasing ordinarily produced by the body naturally. factors, e.g Corticorelin. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally. 2.3 Growth Hormone (GH) its fragments and releasing factors, including, but not limited to: S2. PEPTIDE HORMONES, GROWTH Growth Hormone fragments, e.g. FACTORS, RELATED SUBSTANCES, AOD-9604 and hGH 176-191; AND MIMETICS Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. The following substances, and other CJC-1293, CJC-1295, sermorelin and substances with similar chemical structure or tesamorelin; similar biological effect(s), are prohibited: Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin 1. Erythropoietins (EPO) and agents affecting mimetics, e.g. erythropoiesis, including, but not limited to: anamorelin, ipamorelin and tabimorelin; 1.1 Erythropoietin-Receptor Agonists,e.g. GH-Releasing Peptides (GHRPs), e.g. Darbepoietin (dEPO); alexamorelin, GHRP-1, GHRP-2 Erythropoietins (EPO); (pralmorelin), GHRP-3, GHRP-4, EPO based constructs [EPO-Fc, GHRP-5, GHRP-6, and hexarelin. methoxy polyethylene glycol-epoetin beta (CERA)]; 3. Growth Factors and Growth Factor EPO-mimetic agents and their Modulators, including but not limited to: constructs (e.g. CNTO 530, Fibroblast Growth Factors (FGFs); peginesatide). Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its 1.2 Hypoxia-inducible factor (HIF) analogues; activating agents, e.g. Mechano Growth Factors (MGFs); Argon; Platelet-Derived Growth Factor (PDGF); Cobalt; Thymosin-β4 and its derivatives e.g. TB- Molidustat; 500; Roxadustat (FG-4592); Vascular-Endothelial Growth Factor Xenon. (VEGF). 1.3 GATA inhibitors, e.g. Additional growth factors or growth factors K-11706. modulators affecting muscle, tendon or ligament protein synthesis/degradation, 1.4 TGF-beta (TGF-β) inhibitors, e.g. vascularisation, energy utilisation, regenerative Luspatercept; capacity or fibre type switching. Sotatercept. 1.5 Innate repair receptor agonists, e.g. Asialo EPO; Carbamulated EPO (CEPO). 3 S3. BETA-2 AGONISTS S4. HORMONE AND METABOLIC MODULATORS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. The following hormone and metabolic modulators are prohibited: Including, but not limited to: 1. Aromatase inhibitors including, but not Fenoterol; limited to: Formoterol, 4-Androstene-3,6,17 trione (6-oxo); Higenamine; Aminoglutethimide; Indacaterol; Anastrozole; Androsta-1,4,6-triene-3,17- Olodaterol; dione (androstatrienedione); Procaterol; Androsta-3,5-diene-7,17-dione Reproterol; (arimistane); Exemestane; Salbutamol; Formestane; Salmeterol; Letrozole; Terbutaline; Testolactone. Tulobuterol; Vilanterol. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Except: Raloxifene; Inhaled salbutamol: maximum Tamoxifen; 1600 micrograms over 24 hours in divided Toremifene. doses not to exceed 800 micrograms over 12 hours starting from any dose; 3. Other anti-estrogenic substances including, Inhaled formoterol: maximum delivered but not limited to: dose 54 micrograms over 24 hours; Clomiphene; Inhaled salmeterol: maximum Cyclofenil; 200 micrograms over 24 hours. Fulvestrant. The presence in urine of salbutamol in excess 4. Agents modifying myostatin function(s) of 1000 ng/mL or formoterol in excess of including, but not limited, to: myostatin 40 ng/mL is not consistent with therapeutic use inhibitors. of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the 5. Metabolic modulators: Athlete proves, through a controlled pharmacokinetic study, that the abnormal 5.1 Activators of the AMP-activated result was the consequence of the use of a protein kinase (AMPK), e.g. AICAR, therapeutic dose (by inhalation) up to the SR9009; maximum dose indicated above. and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2- (2-methyl-4-((4-methyl-2-(4- (trifluoromethyl)phenyl)thiazol-5- yl)methylthio)phenoxy) acetic acid (GW1516, GW501516); 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. ETS 135 – Anti-Doping Convention, 16.XI.1989 - The 2018 Prohibited List __________________________________________________________________________________ S5. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide;